Education
About Us
Working with TipRanks
Follow Us
STRATEC Biomedical AG (GB:0RAR)
LSE:0RAR
Total Valuation
STRATEC Biomedical has a market cap or net worth of €267.43M. The enterprise value is €0.00.
Market Cap€267.43M
Enterprise Value€0.00
Share Statistics
STRATEC Biomedical has 12,157,841 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,157,841
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
STRATEC Biomedical’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 5.13%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)5.13%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee176.21K
Profits Per Employee10.96K
Employee Count1,462
Asset Turnover0.58
Inventory Turnover1.54
Valuation Ratios
The current PE Ratio of STRATEC Biomedical is 16.8. STRATEC Biomedical’s PEG ratio is 4.75.
PE Ratio16.8
PS Ratio1.41
PB Ratio1.49
Price to Fair Value1.49
Price to FCF11.87
Price to Operating Cash Flow10.86
PEG Ratio4.75
Income Statement
In the last 12 months, STRATEC Biomedical had revenue of 257.62M and earned 16.02M in profits. Earnings per share was 1.32.
Revenue257.62M
Gross Profit76.39M
Operating Income28.18M
Pretax Income22.01M
Net Income16.02M
EBITDA47.34M
Earnings Per Share (EPS)1.32
Cash Flow
In the last 12 months, operating cash flow was 21.85M and capital expenditures -14.76M, giving a free cash flow of 7.09M billion.
Operating Cash Flow21.85M
Free Cash Flow7.09M
Free Cash Flow per Share0.58
Dividends & Yields
STRATEC Biomedical pays an annual dividend of €0.6, resulting in a dividend yield of 2.7%
Dividend Per Share€0.6
Dividend Yield2.7%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change-19.91%
50-Day Moving Average23.42
200-Day Moving Average25.55
Relative Strength Index (RSI)47.21
Average Volume (3m)2.34K
Important Dates
STRATEC Biomedical upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 7, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
STRATEC Biomedical as a current ratio of 2.47, with Debt / Equity ratio of 54.37%
Current Ratio2.47
Quick Ratio1.17
Debt to Market Cap0.32
Net Debt to EBITDA1.76
Interest Coverage Ratio4.89
Taxes
In the past 12 months, STRATEC Biomedical has paid 5.99M in taxes.
Income Tax5.99M
Effective Tax Rate0.27
Enterprise Valuation
STRATEC Biomedical EV to EBITDA ratio is 9.41, with an EV/FCF ratio of 14.60.
EV to Sales1.73
EV to EBITDA9.41
EV to Free Cash Flow14.60
EV to Operating Cash Flow9.15
Balance Sheet
STRATEC Biomedical has €24.01M in cash and marketable securities with €132.24M in debt, giving a net cash position of -€108.23M billion.
Cash & Marketable Securities€24.01M
Total Debt€132.24M
Net Cash-€108.23M
Net Cash Per Share-€8.90
Tangible Book Value Per Share€10.58
Margins
Gross margin is 30.32%, with operating margin of 10.94%, and net profit margin of 6.22%.
Gross Margin30.32%
Operating Margin10.94%
Pretax Margin8.54%
Net Profit Margin6.22%
EBITDA Margin18.38%
EBIT Margin10.83%
Analyst Forecast
The average price target for STRATEC Biomedical is €34.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€34.00
Price Target Upside53.15% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―